Bayer AG

General information
Bayer AG
Kaiser-Wilhelm-Allee 1
51368 Leverkusen, North Rhine-Westphalia

Contact person: Thomas Kornek, Senior Manager, Investor Relations
Company main phone: +49 (214) 301
Year founded:1863
Source of foundation:Independent foundation
No. of employees: Worldwide:  97922
Corporate description / mission:
Bayer AG is a German chemical and pharmaceutical company, which focuses on human and veterinary pharmaceuticals; consumer healthcare products; agricultural chemicals and biotechnology products; and polymers. The company's products include adempas, adalat, baytril, etc.
State of ownership: Publicly listed on stock exchange
Headquarters: Yes
IPO (year): 1988
  • Pharma (fully integrated)
  • Anti-infectives
  • Antibodies
  • Cell therapy
  • Gene therapy
  • Immunotherapy
  • Nucleic acid drugs
  • Peptides
  • Small molecule therapeutics
  • Stem cells
Primary therapeutic areas:
  • Cardiovascular / cardiology
  • Digestive system / gastroenterology
  • Diseases of the blood and blood-forming organs & immune disorders / hematology / immunology
  • Diseases of the eye / ophthalmology
  • Diseases of the nervous system / neurology
  • Endocrine, nutritional and metabolic diseases / endocrinology
  • Genitourinary system / Urology
  • Infectious and parasitic diseases / infectiology / parasitology
  • Musculoskeletal system and connective tissue / Orthopedics
  • Neoplasms / cancer / oncology
  • Respiratory / pulmonology
  • Symptoms, signs and abnormal clinical and laboratory findings, not elsewhere classified
Business model:
  • Manufacturer
  • R&D
  • Supplier / Distributor
Customer segments:
  • Consumers (mass market)
  • Hospitals
  • Physicians / doctors
  • Direct (own sales force)
Summary Products / Services / Technologies
Number of Biotech Products
Phase I:23
Phase II:9
Phase III:12
On the market:7
Description of products:
Anetumab Ravtansine for cancer multi indication
Anti-FXI Antibody - Anticoagulation
Anti-TFP1 antibody for Hemophilia
Copanlisib (PI3K Inhibitor) for Cancer, etc
Financing details
Fiscal year (end of) 2022
Revenues:EUR 50'739.00M
R&D expenses:EUR 6'572.00M
Net earnings:EUR 4'150.00M
No. of shares:982'424'000
Market cap. / valuation:EUR 54'612.95M